REG - Indivior PLC - Indivior Settles Patent Dispute with Actavis

IndiviorAnnouncement

20/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231220:nRST3885Xa&default-theme=true

RNS Number : 3885X  Indivior PLC  20 December 2023

Indivior Settles Patent Dispute with Teva Subsidiary Actavis

 

Richmond, VA and Slough UK, December 20, 2023 - Indivior PLC (LSE/NASDAQ:
INDV), a leading addiction treatment company, today announced that its
subsidiaries Indivior Inc. and Indivior UK Limited (together, "Indivior")
entered into a settlement agreement with Actavis Laboratories UT, Inc.
("Actavis"), a subsidiary of Teva Pharmaceuticals, to resolve patent disputes
regarding Actavis's Abbreviated New Drug Application ("ANDA") for generic
buprenorphine and naloxone sublingual film. Under the agreement, Indivior
granted Actavis a license to U.S. Patent No. 11,135,216 that would enable
Actavis to launch the generic film products identified in its ANDA in the
United States no earlier than January 31, 2025, unless the unexpired patent
claims are found invalid or unenforceable before that time in a final judicial
decision.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat addiction and serious mental illnesses.
Our vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of substance use disorder (SUD). Indivior is dedicated to transforming SUD
from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in 37
countries worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

 

 

Media Contacts:

 

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts:

 

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGBBDDDGDDGXG